Predictors for the development of ovarian hyperstimulation syndrome in an IVF program


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To investigate the prognostic value of clinical and laboratory markers in the development of ovarian hyperstimulation syndrome (OHSS), which are used at different stages of implementing an in vitro fertilization program. Subjects and methods. Fifty current Russian and foreign literature sources dealing with the problem of OHSS in assisted reproductive technology (ART) programs were analyzed. Results. The paper emphasizes the most important and valid results of these investigations. Assessment of the role of molecular genetic markers as predictors of OHSS and the possibilities of their use in the practice of ART occupy a special place. Conclusion. OHSS is a topical and interesting problem from both scientific and practical standpoints and calls for further investigation.

Full Text

Restricted Access

About the authors

Daria Andreevna Strelchenko

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: da_strelchenko@mail.ru
graduate student of Research Center of Obstetrics

Svetlana Grigorievna Perminova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: perisvet@list.ru
MD, leading researcher of the 1st gynecological department

A. E Donnikov

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: donnikov@dna-technology.ru
PhD, senior staff scientist of laboratory of molecular genetic methods

References

  1. Madill J.J., Mutten N.B., Harrison B.P. Ovarian hyperstimulation syndrome: a potentially fatal complication of early pregnancy. J. Emerg. Med. 2008; 35(3): 283-6.
  2. Alama P., Bettver J., Vidal C., Giles J. GnRH analogues in the prevention of ovarian hyperstimulation syndrome. Int. J. Endocrinol. Metab. 2013 Spring; 11(2): 107-16.
  3. Budev M.M., Arroliga A.C., Falcone T. Ovarian hyperstimulation syndrome. Crit. Care Med. 2005; 3(10, Suppl.): S301-6.
  4. Корнеева И.Е., Калинина Е.А., Сароян Т.Т., Смольникова В.Ю., Серебренникова К.Г., Пырегов А.В., Сухих Г.Т. Федеральные клинические рекомендации. Диагностика и лечение синдрома гиперстимуляции яичников. М.: Российское общество акушеров-гинекологов; 2013. 27с.
  5. Li H.W., Lee V.C., Lau E.Y., Yeung W.S., Ho P.C., Ng E.H. Cumulative livebirth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment. J. Assist. Reprod. Genet. 2014; 31(2): 205-11.
  6. Nastri C.O., Ferriani R.A., Rocha I.A., Martins W.P. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J. Assist. Reprod. Genet. 2010; 27(2-3): 121-8.
  7. Delvigne A., Rosenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update. 2002; 8(6): 559-77.
  8. Enskog A., Henriksson M., Unander M., Nilsson L., Brännström M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil. Steril. 1999; 71(5): 808-14.
  9. Evbuomwan I.O., Davison J.M., Murdoch A.P. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox. Fertil. Steril. 2000; 74(1): 67-72.
  10. Kwee J., Elting M.E., Schats R., McDonnell J., Lambalk C.B. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod. Biol. Endocrinol. 2007; 5: 9
  11. Broekmans F.J., de Ziegler D., Howles C.M., Gougeon A., Trew G., Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil. Steril. 2010; 94(3): 1044-51.
  12. Broekmans F.J., Visser J.A., Laven J.S., Broer S.L., Themmen A.P., Fauser B.C. Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol. Metab. 2008; 19(9): 340-7.
  13. Fréour T., Mirallié S., Bach-Ngohou K., Denis M., Barrière P., Masson D. Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin. Chim. Acta. 2007; 375(1-2): 162-4.
  14. Li H.W., Ng E.H., Wong B.P., Anderson R.A., Ho P.C., Yeung W.S. Correlation between three assay systems for anti-Müllerian hormone (AMH) determination. J. Assist. Reprod. Genet. 2012; 29(12): 1443-6.
  15. Gnoth C., Schuring A.N., Friol K., Tigges J., Mallmann P., Godehardt E. Relevance of anti-Müllerian hormone measurement in a routine IVF program. Hum. Reprod. 2008; 23(6): 1359-65.
  16. La Marca A., Giulini S., Tirelli A., et al. Anti- Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum. Reprod. 2007; 22(3): 766-71.
  17. Lee T.H., Liu C.H., Huang C.C., Wu Y.L., Shih Y.T., Ho H.N., Yang Y.S., Lee M.S. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum. Reprod. 2008; 23(1): 160-7.
  18. Kligman I., Rosenwaks Z. Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil. Steril. 2001; 76(6): 1185-90.
  19. Nardo L.G., Gelbaya T.A., Wilkinson H., Roberts S.A., Yates A., Pemberton P., Laing I. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil. Steril. 2009; 92(5): 1586-93.
  20. Knauff E.A., Eijkemans M.J., Lambalk C.B., ten Kate-Booij M.J., Hoek A., Beerendonk C.C. et al. Anti-Müllerian hormone, inhibin B., and antral follicle count in young women with ovarian failure. J. Clin. Endocrinol. Metab. 2009; 94(3): 786-92.
  21. Gurbuz A.S., Gode F., Ozcimen N., Isik A.Z. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod. Biomed. Online. 2014; 29(5): 541-4.
  22. Papanikolaou E.G., Pozzobon C., Kolibianakis E.M., Camus M., Tournaye H., Fatemi H.M. et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil. Steril. 2006; 85(1): 112-20.
  23. Practice Committee of American Society for Reproductive Medicine. Fertil. Steril. 2008; 90(5, Suppl.).
  24. Shapiro B.S., Daneshmand S.T., Garner F.C., Aguirre M., Ross R., Morris S. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization. Fertil. Steril. 2005; 84(1): 93-8.
  25. Nordhoff V., Gromoll J., Simoni M. Constitutively active mutations of G. protein-coupled receptors: the case of the human luteinizing hormone and follicle-stimulating hormone receptors. Arch. Med. Res. 1999; 30(6): 501-9.
  26. Simoni M., Tempfer C.B., Destenaves B., Fauser B. Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response. Hum. Reprod. Update. 2008;14(5): 459-84.
  27. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B. et al. The structure of haplotype blocks in the human genome. Science. 2002; 296(5576): 2225-9.
  28. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21(2): 263-5.
  29. Barrett J.C. Haploview: visualization and analysis of SNP genotype data. Cold Spring Harb. Protoc. 2009; 2009(10): pdb.ip71.
  30. Liao W.X., Goh H.H., Roy A.C. Functional characterization of a natural variant of luteinizing hormone. Hum. Genet. 2002; 111(2): 219-24.
  31. Alviggi C., Clarizia R., Pettersen K., Mollo A., Humaidan P., Strina I. et al. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod. Biomed. Online. 2009; 18(1): 9-14.
  32. Gromoll J., Lahrmann L., Godmann M., Muller T., Michel C., Stamm S., Simoni M. Genomic checkpoints for exon 10 usage in the luteinizing hormone receptor type 1 and type 2. Mol. Endocrinol. 2007; 21(8): 1984-96.
  33. Gerasimova T., Thanasoula M.N., Zattas D., Seli E., Sakkas D., Lalioti M.D. Identification and in vitro characterization of follicle stimulating hormone (FSH) receptor variants associated with abnormal ovarian response to FSH. J. Clin. Endocrinol. Metab 2010; 95(2): 529-36.
  34. Behre H.M., Greb R.R., Mempel A., Sonntag B., Kiesel L., Kaltwasser P. et al. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet. Genomics. 2005; 15(7): 451-6.
  35. Smits G., Olatunbosun O., Delbaere A., Pierson R., Vassart G., Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N. Engl. J. Med. 2003; 349(8): 760-6.
  36. Vasseur C., Rodien P., Beau I., Desroches A., Gérard C., de Poncheville L. et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N. Engl. J. Med. 2003; 349(8): 753-9.
  37. Montanelli L., Van Durme J.J., Smits G., Bonomi M., Rodien P., Devor E.J. et al. Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor. Mol. Endocrinol. 2004; 18(8): 2061-73.
  38. Dieterich M., Bolz M., Reimer T., Costagliola S., Gerber B. Two different entities of spontaneous ovarian hyperstimulation in a woman with FSH receptor mutation. Reprod. Biomed. Online. 2010; 20(6): 751-8.
  39. Montanelli L., Delbaere A., Di Carlo C., Nappi C., Smits G., Vassart G., Costagliola S. A Mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J. Clin. Endocrinol. Metab. 2004; 89: 1255-8.
  40. De Leener A., Caltabiano G., Erkan S., Idil M., Vassart G., Pardo L., Costagliola S. Identification of the first germline mutation in the extracellular domain of the follitropin receptor responsible for spontaneous ovarian hyperstimulation syndrome. Hum. Mutat. 2008; 29(1): 91-8.
  41. Perez Mayorga M., Gromoll J., Behre H.M., Gassner C., Nieschlag E., Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J. Clin. Endocrinol. Metab. 2000; 85(9): 3365-9.
  42. Daelemans C., Smits G., de Maertelaer V., Costagliola S., Englert Y., Vassart G., Delbaere A. Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J. Clin. Endocrinol. Metab. 2004; 89(12): 6310-5.
  43. O’Brien T.J., Kalmin M.M., Harralson A.F., Clark A.M., Gindoff I., Simmens S.J. et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod. Biol. Endocrinol. 2013; 11: 71.
  44. Gaunt T.R., Rodriguez S., Day I.N. Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX’. BMC Bioinformatics. 2007; 8: 428.
  45. Hanevik H.I., Hilmarsen H.T., Skjelbred C.F., Tanbo T., Kahn J.A. A single nucleotide polymorphism in BMP15 is associated with high response to ovarian stimulation. Reprod. Biomed. Online. 2011; 23(1): 97-104.
  46. Cerrillo M., Pacheco A., Rodriguez S., Gomez R., Delgado F., Pellicer A., Garcia-Velasco J.A. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. Fertil. Steril. 2011; 95(8): 2517-9.
  47. Wang T.H., Horng S.G., Chang C.L., Wu H.M., Tsai Y.J., Wang H.S., Soong Y.K. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J. Clin. Endocrinol. Metab. 2002; 87(7): 3300-8.
  48. Hanevik H.I., Hilmarsen H.T., Skjelbred C.F. Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype. Gynecol. Endocrinol. 2012; 28(11): 845-9.
  49. Nouri K., Haslinger P., Szabo L., Sator M., Schreiber M., Schneeberger C., Pietrowsk D. Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)-a retrospective case-control study. J. Ovarian Res. 2014; 7: 54.
  50. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N.J. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 1994; 269(41): 25646-54.
  51. Jin P.Y., Lu Y.C., Li L., Han Q.F. Co action of CFTR and AQP1 increases permeability of peritoneal epithelial cells on estrogen-induced ovarian hyperstimulation syndrome. BMC Cell Biol. 2012; 13: 23.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies